Molecular Structure of Buserelin (CAS NO.57982-77-1):

IUPAC Name: (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide 
Empirical Formula: C₆₀H₈₆N₁₆O₁₃
Molecular Weight: 1239.4242
H bond acceptors: 29
H bond donors: 17
#Freely Rotating Bonds: 35
Index of Refraction: 1.671
Molar Refractivity: 322.31 cm³
Molar Volume: 861.4 cm³
Surface Tension: 60.7 dyne/cm
Density: 1.43 g/cm³
EINECS: 261-061-9
Classification Code: Drug / Therapeutic Agent; Fertility agents, female; Hormone; Human Data; Reproductive Control Agents; Reproductive Effect
InChI=1/C60H86N16O13/c1-7-64-57(87)48-15-11-23-76(48)58(88)41(14-10-22-65-59(61)62)69-51(81)42(24-33(2)3)70-56(86)47(31-89-60(4,5)6)75-52(82)43(25-34-16-18-37(78)19-17-34)71-55(85)46(30-77)74-53(83)44(26-35-28-66-39-13-9-8-12-38(35)39)72-54(84)45(27-36-29-63-32-67-36)73-50(80)40-20-21-49(79)68-40/h8-9,12-13,16-19,28-29,32-33,40-48,66,77-78H,7,10-11,14-15,20-27,30-31H2,1-6H3,(H,63,67)(H,64,87)(H,68,79)(H,69,81)(H,70,86)(H,71,85)(H,72,84)(H,73,80)(H,74,83)(H,75,82)(H4,61,62,65)
c1(c2c(cccc2)[nH]c1)C[C@@H](NC([C@@H](Cc1c[nH]cn1)NC([C@@H]1CCC(N1)=O)=O)=O)C(N[C@@H](C(N[C@@H](Cc1ccc(O)cc1)C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N1[C@@H](CCC1)C(NCC)=O)=O)CCCNC(N)=N)=O)CC(C)C)=O)COC(C)(C)C)=O)=O)CO)=O

  Buserelin (CAS NO.57982-77-1) may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, estrogen-dependent conditions (such as endometriosis or uterine fibroids), and in assisted reproduction.

Human systemic effects by inhalation: blood pressure elevation. Experimental reproductive effects. When heated to decomposition it emits toxic fumes of NO_x.

  Buserelin , with CAS number of 57982-77-1, can be called (d-ser(bu(supt)(sup6)))-lh-rh(1-9)nonapeptide-ethylamide;(d-ser(tbu)(sup6)-ea(sup10))-lhrh;(d-ser(tbu)(sup6)-ea(sup10))-luteinizinghormone-releasinghormon ; d-ser(tbu(sup6))-lh-rh-(1-9)-nonapeptideethylamide ; d-ser-(tbu)(sup6)-lhrh-ethylamide ; (d-ser(tbu)(sup6)-ea(sup10))-luteinizinghormone-releasinghormone ; etilamide . Buserelin (CAS NO.57982-77-1) is normally delivered via a nasal spray but is also available as an injection. Buserelin acetate is marketed by Sanofi-Aventis under the brand name Suprefact and a generic form of Buserelin is now produced by CinnaGen under the brand name CinnaFact.